Hide metadata

dc.date.accessioned2022-12-09T17:55:15Z
dc.date.available2022-12-09T17:55:15Z
dc.date.created2022-05-30T15:50:38Z
dc.date.issued2022
dc.identifier.citationFan, Zhirui Zheng, Yuanyuan Li, Xiaoli Deng, Xiaoming Ba, Yan Feng, Kun Su, Jin Wang, Hui Suo, Zhenhe Li, Lifeng . Promoting role of pentraxin-3 in esophageal squamous cell carcinoma. Molecular Therapy - Oncolytics. 2022, 24, 772-787
dc.identifier.urihttp://hdl.handle.net/10852/98048
dc.description.abstractPentraxin 3 (PTX3) is an inflammatory molecule that is closely related to the proliferation, invasion, and metastasis of cancer. In order to explore the role of PTX3 in the occurrence and development of esophageal carcinoma (ESCA), we modified the PTX3 gene in ESCA cell lines to obtain the model of gene knockout and overexpression and studied cell proliferation, cycle, apoptosis, migration ability, energy metabolism, and sensitivity to chemotherapy and radiotherapy. We observed the increase in cell proliferation, cycle, apoptosis, migration ability, and sensitivity to chemotherapy and radiotherapy in the PTX3 knockout model, while in the PTX3 overexpression model, these phenomena were significantly reduced. Knockout of the PTX3 also resulted in decreased cell glycolysis and increased oxidative phosphorylation, which is consistent with other findings that PTX3 affects the tumorigenic ability of cells and their sensitivity to docetaxel. In ESCA, SOX9 directly regulates the expression of PTX3, while human leukocyte antigen (HLA)-system-related genes are significantly up-regulated when lacking PTX3. These results indicate that SOX9 may play a crucial role in regulating PTX3 and affecting the HLA system in ESCA.
dc.languageEN
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titlePromoting role of pentraxin-3 in esophageal squamous cell carcinoma
dc.title.alternativeENEngelskEnglishPromoting role of pentraxin-3 in esophageal squamous cell carcinoma
dc.typeJournal article
dc.creator.authorFan, Zhirui
dc.creator.authorZheng, Yuanyuan
dc.creator.authorLi, Xiaoli
dc.creator.authorDeng, Xiaoming
dc.creator.authorBa, Yan
dc.creator.authorFeng, Kun
dc.creator.authorSu, Jin
dc.creator.authorWang, Hui
dc.creator.authorSuo, Zhenhe
dc.creator.authorLi, Lifeng
cristin.unitcode185,53,18,13
cristin.unitnameAvdeling for patologi
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin2028196
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Molecular Therapy - Oncolytics&rft.volume=24&rft.spage=772&rft.date=2022
dc.identifier.jtitleMolecular Therapy - Oncolytics
dc.identifier.volume24
dc.identifier.startpage772
dc.identifier.endpage787
dc.identifier.doihttps://doi.org/10.1016/j.omto.2022.02.005
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn2372-7705
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution-NonCommercial-NoDerivatives 4.0 International
This item's license is: Attribution-NonCommercial-NoDerivatives 4.0 International